Bozitinib
Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].
Product Specifications
CAS Number
1440964-89-5
Product Name Alternative
PLB-1001; CBT-101; Vebreltinib
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
C-Met/HGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bozitinib.html
Purity
98.88
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CN1N=C2C=C(F)C(C(C3=NN=C4C=CC(C5=CN(C6CC6)N=C5)=NN43)(F)F)=CC2=C1
Molecular Formula
C20H15F3N8
Molecular Weight
424.38
Precautions
H302, H315, H319
References & Citations
[1]Hu H, et al. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell. 2018 Nov 29;175 (6) :1665-1678.e18.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MUC16 / CA125 (Ovarian Carcinoma Marker) (OCA125/2349R), 0.2mg/mL
![GM CSF (CSF2) Mouse Monoclonal Antibody [Clone ID: OTI4B2]](https://cdn.genprice.uk/products/937/68dd18b9061270361e90821d/imageurl/cf808008.webp)